Below are the most recent publications written about "Muscular Dystrophy, Duchenne" by people in Profiles.
-
Wong BL, Cook T, Miller H. Prednisone and deflazacort in Duchenne muscular dystrophy: a patient perspective and plain language summary publication of the Cincinnati study. J Comp Eff Res. 2022 Aug; 11(11):779-786.
-
Flotte TR. Precision of Exon Skipping with U7 Constructs. Hum Gene Ther. 2021 11; 32(21-22):1315-1316.
-
Dhindsa JS, McCall AL, Strickland LM, Fusco AF, Kahn AF, ElMallah MK. Motor axonopathies in a mouse model of Duchenne muscular dystrophy. Sci Rep. 2020 06 02; 10(1):8967.
-
Shih JA, Folch A, Wong BL. Duchenne Muscular Dystrophy: the Heart of the Matter. Curr Heart Fail Rep. 2020 06; 17(3):57-66.
-
Bylo M, Farewell R, Coppenrath VA, Yogaratnam D. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy. Ann Pharmacother. 2020 08; 54(8):788-794.
-
Varsanik JS, Kimmel ZM, Laforet GA, Ricotti V, Sajeev G, Signorovitch J, Quiroz JA, Chevalier TW. Validation of an ambient measurement system (AMS) for physical activities in a paediatric population. J Med Eng Technol. 2019 Apr; 43(3):182-189.
-
Gonzalez D, Rebolledo DL, Correa LM, Court FA, Cerpa W, Lipson KE, van Zundert B, Brandan E. The inhibition of CTGF/CCN2 activity improves muscle and locomotor function in a murine ALS model. Hum Mol Genet. 2018 08 15; 27(16):2913-2926.
-
Gordish-Dressman H, Willmann R, Dalle Pazze L, Kreibich A, van Putten M, Heydemann A, Bogdanik L, Lutz C, Davies K, Demonbreun AR, Duan D, Elsey D, Fukada SI, Girgenrath M, Patrick Gonzalez J, Grounds MD, Nichols A, Partridge T, Passini M, Sanarica F, Schnell FJ, Wells DJ, Yokota T, Young CS, Zhong Z, Spurney C, Spencer M, De Luca A, Nagaraju K, Aartsma-Rus A. "Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic. J Neuromuscul Dis. 2018; 5(4):407-417.
-
Wong BL, Rybalsky I, Shellenbarger KC, Tian C, McMahon MA, Rutter MM, Sawnani H, Jefferies JL. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment. J Pediatr. 2017 03; 182:296-303.e1.
-
Aartsma-Rus A, Krieg AM. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther. 2017 02; 27(1):1-3.